Dengue Vaccine: The Need, the Challenges, and Progress

Journal of Infectious Diseases

Volumn 214, Issue 6, 2016, Pages 825-827

  Rothman, Alan L ^a   Ennis, Francis A ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

dengue; dengue vaccine; live virus vaccine; protective immunity; vaccine clinical trial

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; TV003; UNCLASSIFIED DRUG; LIVE VACCINE;

AEDES; ANTIBODY RESPONSE; CORRELATION ANALYSIS; DENGUE; DENGUE VIRUS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LICENCE; NOTE; PRIORITY JOURNAL; RASH; SEROTYPE; VIREMIA; IMMUNOLOGY;

DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; VACCINES, ATTENUATED;

EID: 84985017704     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw068     Document Type: Note

References (10)

1. Thomas SJ, Rothman AL. Trials and tribulations on the path to developing a dengue vaccine. Vaccine 2015; 33(suppl 4):D24-31.
2. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
3. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. New Engl J Med 2015; 373:1195-206.
4. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigationalmonovalentDENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011; 29:7242-50.
5. Durbin AP, Kirkpatrick BD, Pierce KK, et al. A 12- month-interval dosing study in adults indicates that a single dose of the National Institutes of Allergy and Infectious Diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis 2016; 214:832-5.
6. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014; 5:446.
7. Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995; 754:289-99.
8. Ennis FA. Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination- inhibiting antibodies. J Infect Dis 1969; 119: 654-7.
9. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of pre-existing dengue virus (DV) neutralizing antibody levels to viremia and disease severity in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000.
10. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A 2016; 113:728-33.